Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Диарея путешественников
Диарея путешественников
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Diemert DJ. Prevention and Self–Treatment of Traveler’s Diarrhea. Clin Microb Rev 2006; 19 (3): 583–94.
2. Gascon J. Epidemiology, etiology and pathophysiology of traveler’s diarrhea. Bacterial flora in digestive disease. Focus on Rifaximin. Eds. C. Scarpignato, A. Lanas. Basel: Karger, 2006: p. 162–73.
3. Крумс Л.М. Хроническая диарея: патогенез и лечение. Эксперим. и клин. гастроэнтерология. 2002; 4: 84–8.
4. Castelli F, Saleri N, Tomasoni LR, Carosi G. Prevention and treatment of traveler’s diarrhea. Focus on antimicrobial agents. Bacterial flora in digestive disease. Focus on Rifaximin. Eds. C. Scarpignato, A. Lanas. Basel: Karger, 2006: p. 174–90.
5. Czerucka D, Roux I, Rampal P. Saccharomyces boulardi inhibits secretagogue-mediated adenosine 3’5’ cyclic monophosphte induction in intestinal cells. Gastroenterol 1994; 106: 65–72.
6. Pothoulakis C, Kelly C, Joshi M. Saccharomyces boulardi inhibits Clostridium difficile toxin A and enterotoxity in rat ileum. Gastroenterol 1993; 103: 1108–15.
7. Sougioultzis S, Simeonidis S, Bhaskar KR et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343 (1): 69–76.
8. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007; 5: 97–105.
2. Gascon J. Epidemiology, etiology and pathophysiology of traveler’s diarrhea. Bacterial flora in digestive disease. Focus on Rifaximin. Eds. C. Scarpignato, A. Lanas. Basel: Karger, 2006: p. 162–73.
3. Крумс Л.М. Хроническая диарея: патогенез и лечение. Эксперим. и клин. гастроэнтерология. 2002; 4: 84–8.
4. Castelli F, Saleri N, Tomasoni LR, Carosi G. Prevention and treatment of traveler’s diarrhea. Focus on antimicrobial agents. Bacterial flora in digestive disease. Focus on Rifaximin. Eds. C. Scarpignato, A. Lanas. Basel: Karger, 2006: p. 174–90.
5. Czerucka D, Roux I, Rampal P. Saccharomyces boulardi inhibits secretagogue-mediated adenosine 3’5’ cyclic monophosphte induction in intestinal cells. Gastroenterol 1994; 106: 65–72.
6. Pothoulakis C, Kelly C, Joshi M. Saccharomyces boulardi inhibits Clostridium difficile toxin A and enterotoxity in rat ileum. Gastroenterol 1993; 103: 1108–15.
7. Sougioultzis S, Simeonidis S, Bhaskar KR et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343 (1): 69–76.
8. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007; 5: 97–105.
Авторы
М.Л.Бабаян
ФГБУ МНИИ педиатрии и детской хирургии Минздрава РФ
ФГБУ МНИИ педиатрии и детской хирургии Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.